(Press-News.org) New research suggests that several commonly prescribed drugs for type 2 diabetes may not be as effective at preventing death and cardiovascular diseases, such as heart attacks and stroke, as the oral anti-diabetic drug, metformin.
Insulin secretagogues (ISs), such as glimepiride, glibenclamide (known as glyburide in the USA and Canada), gliclazide and tolbutamide, have been used to treat type 2 diabetes since the 1950-1970s, Nevertheless, the long-term risk associated with these drugs has largely been unknown. Metformin is the first drug of choice in type 2 diabetes, but, until now, there have not been studies investigating the long-term risk of individual ISs compared with metformin.
A study published online today in the European Heart Journal [1] followed a large, unselected group of everyone living in Denmark, aged over 20, who had been treated with either an IS or metformin (monotherapy) between 1997 and 2006 – a total of 107,806 people. It found that, compared to metformin treatment, monotherapy with most ISs, including glimepiride, glibenclamide, glipizide and tolbutamide, was associated with a greater risk of death from any cause, and a greater risk of heart attacks, stroke or death from cardiovascular diseases. This was the case both for patients who had already suffered a heart attack and for patients who had not. Two other ISs, gliclazide and repaglinide, showed no significant difference to metformin in their effectiveness in patients with and without a history of heart attacks.
Compared to metformin, patients who had not suffered a heart attack had approximately a fifth to a third higher risk of death from any cause if they were taking glimepiride, glibenclamide, glipizide or tolbutamide. In patients with a history of heart attacks, the risk was approximately a third to a half higher.
The researchers, led by Dr Tina Ken Schramm, a senior resident doctor at the Heart Centre at the Rigshospitalet Copenhagen University Hospital (Copenhagen, Denmark), stress that the findings may not mean that these ISs actually cause harm, but only that they appear to be less effective than metformin.
"Previous studies have shown that ISs, in particular sulphonylureas, are associated with a reduction in long-term risk. Therefore, the increased risk from ISs shown in our study presumably has more to do with the beneficial effects of metformin, gliclazide and repaglinide, than the detrimental effect of the other ISs," explained Dr Schramm. "This is the first study to compare all ISs with metformin despite a wide debate on the possible cardiovascular risk associated with ISs for about three decades. Our findings emphasise how important it is to conduct long-term follow up studies of glucose-lowering medications."
In an accompanying editorial [2], Drs Odette Gore and Darren McGuire of the University of Texas Southwestern Medical Center (Dallas, Texas, USA), write that the study's findings are "among the most robust published", and continue: "It is of key importance to note that the observation of less benefit with most sulphonylureas [ISs] in the study compared with metformin should not be interpreted as causing harm."
Dr McGuire explained: "Patients taking metformin had the best outcomes, supporting prior evidence of metformin benefit and making it the first-line drug recommended for almost all patients with type 2 diabetes. Compared against this beneficial drug, most of the ISs were associated with worse outcomes, but they would almost certainly be similar to, or better, had the comparison been made against placebo treatment, with the added benefit on kidney, eye, and nerve disease of the glucose control they yield. So patients should not stop their medications based on this study, but certainly should discuss any concerns with their doctor."
He added: "It's important to remember that these are observational analyses and not randomised comparisons, so it is impossible to tease out what if any of the difference in outcomes is due to the drugs compared versus differences in the patients – those taking ISs might have an increased risk to begin with."
Dr Schramm and her colleagues say that the mechanisms underlying the effects of different ISs and metformin are not fully understood and require further research.
She concluded: "Our study supports previous studies demonstrating that metformin may be less hazardous or more beneficial than most ISs. This suggests that metformin should be the first drug of choice in type 2 diabetes in most patients. The study shows there are important differences in the risk associated with different ISs, suggesting that gliclazide and maybe repaglinide are preferable, although in patients who have had a previous heart attack the most beneficial agents are metformin and gliclazide. As a result of our findings it is important now that there should be randomised studies focusing on patients at low and high cardiovascular risk."
###
Notes:
[1] "Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study". European Heart Journal. doi:10.1093/eurheartj/ehr077
[2] "Resolving drug effects from class effects among drugs for type 2 diabetes mellitus: more support for cardiovascular outcome assessments". European Heart Journal. doi:10.1093/eurheartj/ehr019
[3] ISs act by causing insulin to be released, thereby dealing with the problem of insufficient insulin production seen in type 2 diabetes. Metformin combats insulin resistance – one of the characteristics of diabetes – by increasing the action of insulin on insulin receptors, thereby reducing blood glucose in the liver, muscles and fat. During the period of the study, about 50-60% of those receiving glucose-lowering medications received monotherapy with metformin or ISs in Denmark. The initial treatment for diabetes patients is usually monotherapy with either metformin or ISs, and then later, when the diabetes becomes more advanced, insulin treatment or a combination of treatments becomes an option.
END
International Women in Jazz Festival 2011, featuring The Antoinette Montague Group with Tammy Hall, Bill Easley and Payton Crossley. Held at Saint Peter's Church, 54th Street at Lexington Ave, NYC, on Saturday, April 9, 2011 from 12:30pm to 9:30pm.
International Women in Jazz Festival 2011 schedule:
12:30 - 2:00 pm Masterclass by Melba Joyce
2:15 - 3:15 pm Jam session: Linda Presgrave Trio
4:15 - 5:30 pm IWJ honorees:
Paul Ash, Sam Ash Music Corporation
Rhonda Hamilton, WBGO
Remembering Trudy Pitts by Mr. C
Sally Placksin, Moderator
5:45 - 6:45 pm Reception: ...
Female deer do not always choose the bigger and dominant males to mate with, scientists from Queen Mary, University of London and Hartpury College have found.
The research, which was undertaken in Dublin's Phoenix Park on a herd of fallow deer, focussed on females who chose not to mate with the 'top' males.
The study, published today (6 April) in PLoS ONE found that yearling females tended to mate with a higher proportion of younger, lower ranking males while older females actively avoided mating with them.
Alan McElligott, co-author on the study from Queen Mary, ...
This release is available in Spanish.
SAN JOSÉ, COSTA RICA (7 April 2011)—Crop specialists in Central America announced today that a major rescue effort is underway in one of the heartlands of ancient agriculture to regenerate thousands of unique varieties of coffee, tomatoes, chili peppers, beans and other major crops through a partnership between the Global Crop Diversity Trust and 19 Latin American genebanks.
One of the oldest collections targeted by the project is Costa Rica's Centro Agronómico Tropical de Investigación y Enseñanza (CATIE). An array of challenges—including ...
TMS Funding, the wholesale residential lending channel of Total Mortgage Services, LLC, announced today the hiring of six new Wholesale Account Executives, all with successful track records in developing new business relationships and supporting high quality mortgage brokers.
"We are extremely pleased to have hired such an experienced group of mortgage production professionals that will have an immediate impact on expanding TMS Funding in many key markets and building out our national lending platform," commented Lisa Schreiber, Executive Vice President of Wholesale ...
April 6, 2011 – Developmental processes are increasingly well-characterized at the molecular and cell biological levels, but how more complex tissues and organs involving the coordinated action of multiple cell types in three dimensions is achieved remains something of a black box. One question of particular interest and importance is whether signaling interactions between neighboring tissues are essential to guiding organogenesis, or whether these can arise autonomously from developmental routines inherent to a given primordial tissue. Finding answers to these questions ...
ANN ARBOR, Mich.---Biologically diverse streams are better at cleaning up pollutants than less rich waterways, and a University of Michigan ecologist says he has uncovered the long-sought mechanism that explains why this is so.
Bradley Cardinale used 150 miniature model streams, which use recirculating water in flumes to mimic the variety of flow conditions found in natural streams. He grew between one and eight species of algae in each of the mini-streams, then measured each algae community's ability to soak up nitrate, a nitrogen compound that is a nutrient pollutant ...
Surado Solutions, the developer of on-premise and cloud based Online CRM solutions, announced the deployment of enterprise cloud computer services to deliver its International Cloud SaaS Surado CRM Online initiatives.
Surado's enterprise cloud combines the power and flexibility of infrastructure-as-a-service with the expertise, security and availability that is required for mission-critical computing needs. These services will provide Surado command and control over a cloud-based resource pool of compute, storage and network built on a fully clustered enterprise-class ...
The country's state-funded healthcare service is similar to the NHS, and it also has a larger private healthcare sector, nurses not only find it easy to adapt to familiar working practices but can also expect a better climate, with an 'easy way of life'.
Not surprising then when HCL International, the leading international healthcare recruiter, says that it gets it's best response when targeting Ireland for nursing jobs in Australia. The combination of recession and less favourable working conditions in the public sector is driving increasing numbers of nurses to seek ...
CAMBRIDGE, Mass. -- MIT cancer biologists have identified a genetic change that makes lung tumors more likely to spread to other parts of the body. The findings, to be published in the April 6 online issue of Nature, offers new insight into how lung cancers metastasize and could help identify drug targets to combat metastatic tumors, which account for 90 percent of cancer deaths.
The researchers, led by Tyler Jacks, director of the David H. Koch Institute for Integrative Cancer Research at MIT, found the alteration while studying a mouse model of lung cancer. They then ...
PASADENA, Calif.—For many years, most scientists studying Tibet have thought that a very hot and very weak lower and middle crust underlies its plateau, flowing like a fluid. Now, a team of researchers at the California Institute of Technology (Caltech) is questioning this long-held belief and proposing that an entirely different mechanism is at play.
"The idea that Tibet is more or less floating on a layer of partially molten crust is accepted in the research community. Our research proposes the opposite view: that there is actually a really strong lower crust that originates ...
